Title |
Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1
|
---|---|
Published in |
Molecular Brain, November 2013
|
DOI | 10.1186/1756-6606-6-48 |
Pubmed ID | |
Authors |
Serena Notartomaso, Cristina Zappulla, Francesca Biagioni, Milena Cannella, Domenico Bucci, Giada Mascio, Pamela Scarselli, Francesco Fazio, Filippo Weisz, Luana Lionetto, Maurizio Simmaco, Roberto Gradini, Giuseppe Battaglia, Michele Signore, Aldamaria Puliti, Ferdinando Nicoletti |
Abstract |
Spinocerebellar ataxia type 1 (SCA1) is a genetic disorder characterized by severe ataxia associated with progressive loss of cerebellar Purkinje cells. The mGlu1 metabotropic glutamate receptor plays a key role in mechanisms of activity-dependent synaptic plasticity in the cerebellum, and its dysfunction is linked to the pathophysiology of motor symptoms associated with SCA1. We used SCA1 heterozygous transgenic mice (Q154/Q2) as a model for testing the hypothesis that drugs that enhance mGlu1 receptor function may be good candidates for the medical treatment of SCA1. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 1 | 2% |
Unknown | 54 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 27% |
Student > Ph. D. Student | 9 | 16% |
Student > Master | 6 | 11% |
Other | 4 | 7% |
Student > Doctoral Student | 3 | 5% |
Other | 8 | 15% |
Unknown | 10 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 19 | 35% |
Agricultural and Biological Sciences | 9 | 16% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Chemistry | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Other | 6 | 11% |
Unknown | 13 | 24% |